Fortress Biotech Q1 net loss narrows to $12.7M; Checkpoint acquisition on track

Fortress Biotech, Inc.

2025-Q1 EPS reported -$0.48 vs consensus -$0.50 ▲ beat (+4.9%)

Consolidated net loss $12.7M ($0.48/sh) vs $17.9M ($1.04/sh) in Q1 2024.
Cash $91.3M as of March 31, 2025, up $34.0M from Dec 2024; Checkpoint holds $33.0M.
Emrosi launched in March 2025; first prescriptions filled for inflammatory rosacea lesions.
Checkpoint to be acquired by Sun Pharma for $4.10/sh plus $0.70 CVR; Fortress expects ~$28M at closing.
CUTX-101 NDA priority review with PDUFA Sept 30, 2025; Cyprium retains 100% of any PRV.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.